Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata - A large retrospective study on 142 patients with a self-controlled design

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 4, 2012, Pages 503-507

  Ohlmeier, M C ^a   Traupe, H ^a   Luger, T A ^a   Bohm M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENCYPRONE;

ADULT; AGED; ALOPECIA AREATA; ARTICLE; COHORT ANALYSIS; CONTACT DERMATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAIR GROWTH; HUMAN; IMMUNOTHERAPY; LYMPH NODE SWELING; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALOPECIA AREATA; CHILD; CYCLOPROPANES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84858860773     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04114.x     Document Type: Article

References (24)

1. Safavi K,. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992; 128: 702.
2. van der Steen P, Traupe H, Happle R, et al. The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate. Acta Derm Venereol 1992; 72: 373-375.
3. Redler S, Brockschmidt FF, Forstbauer L, et al. The TRAF1/C5 locus confers risk for familial and severe alopecia areata. Br J Dermatol 2010; 162: 866-869.
4. Dittmar M, Kahaly GJ,. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003; 88: 2983-2992. (Pubitemid 36877459)
5. Hedstrand H, Perheentupa J, Ekwall O, et al. Antibodies against hair follicles are associated with alopecia totalis in autoimmune polyendocrine syndrome type I. J Invest Dermatol 1999; 113: 1054-1058. (Pubitemid 30013352)
6. MacDonald Hull SP, Wood ML, Hutchinson PE, et al. British Association of Dermatologists. Guidelines for the management of alopecia areata. Br J Dermatol 2003; 149: 692-699. (Pubitemid 37419985)
7. Happle R, Cebulla K, Echternacht-Happle K,. Dinitrochlorobenzene therapy for alopecia areata. Arch Dermatol 1978; 114: 1629-1631. (Pubitemid 9063858)
8. Hoffmann R, Happle R,. Topical immunotherapy in alopecia areata. What, how, and why?. Dermatol Clin 1996; 14: 739-744. (Pubitemid 26322542)
9. Firooz A, Bouzari N, Mojtahed F, et al. Topical immunotherapy with diphencyprone in the treatment of extensive and/or long-lasting alopecia areata. J Eur Acad Dermatol Venereol 2005; 19: 393-394. (Pubitemid 40691734)
10. Galadari I, Rubaie S, Alkaabi J, Galadari H,. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA). Eur Ann Allergy Clin Immunol 2003; 35: 397-401. (Pubitemid 38029744)
11. Gordon PM, Aldrige RD, McVittie E, Hunter JA,. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up. Br J Dermatol 1996; 134: 869-871. (Pubitemid 26151401)
12. Monk B,. Induction of hair growth in alopecia totalis with diphencyprone sensitization. Clin Exp Dermatol 1989; 14: 154-157. (Pubitemid 19088563)
13. Sotiriadis D, Patsatsi A, Lazaridou E, et al. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol 2007; 32: 48-51. (Pubitemid 46006366)
14. van der Steen PH, van Baar HM, Happle R, et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991; 24: 227-230.
15. Weise K, Kretzschmar L, John SM, Hamm H,. Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Dermatology 1996; 192: 129-133. (Pubitemid 26072444)
16. Wiseman MC, Shapiro J, MacDonald N, Lui H,. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001; 137: 1063-1068. (Pubitemid 32756464)
17. Avgerinou G, Gregoriou S, Rigopoulos D, et al. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol 2008; 22: 320-323. (Pubitemid 351247421)
18. Pericin M, Trueb RM,. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases. Dermatology 1998; 196: 418-421.
19. Ajith C, Gupta S, Kanwar AJ,. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome. J Drugs Dermatol 2006; 5: 262-266.
20. Blaumeiser B, van der Goot I, Fimmers R, et al. Familial aggregation of alopecia areata. J Am Acad Dermatol 2006; 54: 627-632.
21. McDonagh AJ, Messenger AG,. The pathogenesis of alopecia areata. Dermatol Clin 1996; 14: 661-670. (Pubitemid 26322534)
22. Valsecchi R, Cainelli T, Foiadelli L, Rossi A,. Topical immunotherapy of alopecia areata. A follow-up study. Acta Derm Venereol 1986; 66: 269-272. (Pubitemid 16115873)
23. Case PC, Mitchell AJ, Swanson NA, et al. Topical therapy of alopecia areata with squaric acid dibutylester. J Am Acad Dermatol 1984; 10: 447-450.
24. Bolduc C, Shapiro J,. DPCP for the treatment of alopecia areata. Skin Therapy Lett 2000; 5: 3-4.